Theravance Biopharma (NASDAQ:TBPH) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a strong-buy rating in a research report sent to investors on Sunday morning.

A number of other analysts have also recently issued reports on TBPH. HC Wainwright lifted their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Weiss Ratings upgraded shares of Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, March 24th. B. Riley Financial restated a “neutral” rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a report on Wednesday, March 4th. Oppenheimer lowered shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Finally, Zacks Research upgraded shares of Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a report on Thursday, March 19th. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, Theravance Biopharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

Theravance Biopharma Price Performance

TBPH opened at $16.23 on Friday. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03. The business has a 50-day moving average of $17.32 and a 200-day moving average of $16.95. The company has a market capitalization of $835.68 million, a PE ratio of 8.00 and a beta of 0.17.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the transaction, the senior vice president owned 232,699 shares of the company’s stock, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Quarry LP bought a new position in Theravance Biopharma in the 3rd quarter worth $26,000. Caitong International Asset Management Co. Ltd boosted its holdings in Theravance Biopharma by 107.4% during the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 1,411 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of Theravance Biopharma by 20,269.6% in the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 4,662 shares during the period. 99.10% of the stock is currently owned by institutional investors and hedge funds.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.